Media stories about AxoGen (NASDAQ:AXGN) have been trending somewhat positive recently, Accern Sentiment reports. The research group identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. AxoGen earned a media sentiment score of 0.15 on Accern’s scale. Accern also assigned news headlines about the medical equipment provider an impact score of 45.2659201817039 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
A number of brokerages recently issued reports on AXGN. Leerink Swann upped their price target on shares of AxoGen from $26.00 to $30.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 21st. Lake Street Capital upped their target price on shares of AxoGen from $22.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday, November 21st. Wedbush restated a “buy” rating and set a $27.00 target price (up previously from $22.00) on shares of AxoGen in a research note on Tuesday, November 21st. Cantor Fitzgerald restated an “overweight” rating on shares of AxoGen in a research note on Friday, January 5th. Finally, BidaskClub cut shares of AxoGen from a “strong-buy” rating to a “buy” rating in a research note on Thursday, January 11th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $29.33.
AxoGen (NASDAQ:AXGN) traded down $1.40 during midday trading on Friday, hitting $26.65. 245,069 shares of the stock traded hands, compared to its average volume of 284,486. AxoGen has a 12-month low of $9.55 and a 12-month high of $31.70. The stock has a market cap of $947.81 and a price-to-earnings ratio of -70.13. The company has a quick ratio of 2.95, a current ratio of 3.55 and a debt-to-equity ratio of 1.93.
AxoGen (NASDAQ:AXGN) last released its quarterly earnings results on Wednesday, November 1st. The medical equipment provider reported ($0.06) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.06). AxoGen had a negative net margin of 24.74% and a negative return on equity of 91.00%. The firm had revenue of $16.05 million during the quarter, compared to analyst estimates of $15.55 million. The company’s revenue was up 43.2% compared to the same quarter last year. analysts forecast that AxoGen will post -0.32 EPS for the current fiscal year.
In related news, Director Guido J. Neels sold 1,150,000 shares of the stock in a transaction that occurred on Monday, November 20th. The shares were sold at an average price of $19.74, for a total value of $22,701,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Jamie Mark Grooms sold 84,295 shares of the stock in a transaction that occurred on Friday, December 8th. The stock was sold at an average price of $26.38, for a total transaction of $2,223,702.10. The disclosure for this sale can be found here. Insiders have sold a total of 1,293,990 shares of company stock valued at $26,494,898 in the last ninety days. Insiders own 9.33% of the company’s stock.
TRADEMARK VIOLATION WARNING: “AxoGen (NASDAQ:AXGN) Given Daily Media Impact Rating of 0.15” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another domain, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this article can be read at https://www.dispatchtribunal.com/2018/02/02/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-axogen-axgn-share-price.html.
AxoGen, Inc provides surgical solutions for peripheral nerve injuries. The companys surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.
Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.